The Use of 1α,25-Dihydroxyvitamin D₃ as an Anticancer Agent.
The Use of 1α,25-Dihydroxyvitamin D₃ as an Anticancer Agent.
复制标题
DOI：
10.3390/ijms17050729
复制
发表时间：
2016-05-13
影响因子：
5.6
通讯作者：
Brown G
中科院分区：
文献类型：
--
作者：
Marcinkowska E;Wallace GR;Brown G
维生素D可以影响癌症发病率的观点来自流行病学研究。维生素D的主要来源是皮肤暴露于紫外线B后产生的。早在1941年，人们就首次观察到个人暴露在阳光下与患癌症的可能性之间存在负相关。1980年，加兰和加兰根据对美国结肠癌患者的流行病学研究结果提出假设，认为与阳光本身相反，阳光照射产生的维生素D对癌症有保护作用。后来的研究揭示了阳光照射与前列腺癌和乳腺癌的发生之间的负相关性。这些观察结果促使实验室研究维生素D是否对癌细胞有影响。维生素D对癌细胞没有活性，但最具活性的代谢物1α，25-二羟基维生素D3（1，25 D）具有深远的生物学效应。本文综述了1，25 D的抗癌作用、临床试验及新型低钙类似物的应用前景。
The notion that vitamin D can influence the incidence of cancer arose from epidemiological studies. The major source of vitamin D in the organism is skin production upon exposure to ultra violet-B. The very first observation of an inverse correlation between exposure of individuals to the sun and the likelihood of cancer was reported as early as 1941. In 1980, Garland and Garland hypothesised, from findings from epidemiological studies of patients in the US with colon cancer, that vitamin D produced in response to sun exposure is protective against cancer as opposed to sunlight per se. Later studies revealed inverse correlations between sun exposure and the occurrence of prostate and breast cancers. These observations prompted laboratory investigation of whether or not vitamin D had an effect on cancer cells. Vitamin D is not active against cancer cells, but the most active metabolite 1α,25-dihydroxyvitamin D3 (1,25D) has profound biological effects. Here, we review the anticancer action of 1,25D, clinical trials of 1,25D to date and the prospects of the future therapeutic use of new and low calcaemic analogues.